Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering (Nasdaq: IMRX) announced it is expected to be added to the Nasdaq Biotechnology Index (NBI).

Rhea-AI Summary

Immuneering (Nasdaq: IMRX) announced it is expected to be added to the Nasdaq Biotechnology Index (NBI). The addition is scheduled to become effective prior to market open on Monday, December 22, 2025.

The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is evaluated annually each December. Index membership requires meeting eligibility criteria such as minimum market capitalization, average daily trading volume, and public company seasoning. The NBI is calculated using a modified capitalization-weighted methodology.

Positive

• Index addition effective prior to market open on December 22, 2025
• Eligibility met for NBI minimum market cap, trading volume, and seasoning
• NBI evaluated annually in December (potential recurring review)

Negative

• None.

Argus Dec 16 session

-0.69% close to close Open Argus

Details

News Market Reaction – IMRX

In the Dec 16 session, IMRX declined 0.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights IMRX’s expected addition to the Nasdaq Biotechnology Index effective De...

Analysis

This announcement highlights IMRX’s expected addition to the Nasdaq Biotechnology Index effective December 22, 2025, signaling it meets criteria such as minimum market capitalization and trading volume. Before the news, shares traded at $5.78, above the $4.07 200-day MA yet well below the $10.08 52-week high. Recent history includes sizable financings and positive clinical updates. Investors may watch how index inclusion affects liquidity, ownership mix, and any future use of the registered $300M shelf.

Key Figures

Index inclusion date: December 22, 2025

Index inclusion date

December 22, 2025

Effective date for addition to Nasdaq Biotechnology Index (NBI)

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Conference appearance

   24h Move

   -0.7%

   Announcement of participation in Piper Sandler healthcare conference.

2. Nov 12

   Earnings & clinical

   24h Move

   -1.8%

   Q3 2025 results with positive survival data and strengthened cash.

3. Nov 04

   Earnings preview

   24h Move

   +0.5%

   Scheduling Q3 2025 earnings call and new clinical case studies.

4. Sep 26

   Clinical data call

   24h Move

   -16.5%

   Discussion of Phase 2a overall survival and safety data in pancreatic cancer.

5. Sep 25

   Equity offering

   24h Move

   -13.3%

   Pricing of $175M public offering plus $25M private placement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq biotechnology index, industry classification benchmark, modified capitalization-weighted methodology

3 terms

nasdaq biotechnology index financial

"it is expected to be added to the Nasdaq Biotechnology Index (“NBI”)"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

industry classification benchmark technical

"classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark"

A standardized system that groups companies into industries and sectors based on their main business activities, like a library catalog that puts similar books together. It matters to investors because it enables fair comparisons between peers, guides portfolio construction and sector allocation, determines which stocks belong in industry indexes or ETFs, and helps track industry-level risks and performance trends.

modified capitalization-weighted methodology technical

"The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology"

A modified capitalization-weighted methodology is a way of building a stock index that starts with companies sized by market value but then adjusts those weights to avoid any one firm dominating the index or to reflect additional considerations like tradability or sector balance. For investors, it matters because the adjustments change exposure and risk compared with a pure market-cap index — think of it as giving big players somewhat less voting power at a meeting so the outcome better represents the whole room.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.

For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI

About Immuneering Corporation

Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently planned to be evaluated in a Phase 3 trial in first-line pancreatic cancer, which is expected to begin dosing in mid-2026. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Carson Creehan
202-878-8330
Carson.creehan@padillaco.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Immuneering (IMRX) be added to the Nasdaq Biotechnology Index (NBI)?

Immuneering is expected to be added prior to market open on Monday, December 22, 2025.

What criteria did IMRX meet to join the Nasdaq Biotechnology Index (NBI)?

Index membership requires meeting eligibility such as minimum market capitalization, average daily trading volume, and public company seasoning.

How often is the Nasdaq Biotechnology Index (NBI) evaluated for membership changes?

The NBI is evaluated annually in December.

What weighting method does the Nasdaq Biotechnology Index (NBI) use?

The NBI is calculated under a modified capitalization-weighted methodology.

What does inclusion in the NBI mean for IMRX shareholders on December 22, 2025?

Inclusion becomes effective prior to market open on December 22, 2025; the announcement confirms IMRX met the index eligibility requirements.